Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Endurance RP ( (HK:0575) ) has issued an announcement.
Endurance RP has announced that its commercial partner, Jiangsu Wanbang Biopharmaceutical Group Co., Ltd., has passed the first stage of the New Drug Application review process for Senstend™ with China’s National Medical Products Administration. This development is crucial for the company’s operations in China, as Wanbang Biopharmaceutical is responsible for obtaining regulatory approvals and managing the marketing and distribution of Senstend™. The approval process is expected to conclude within 12 months, potentially leading to significant financial milestones for Endurance RP upon successful commercialization.
More about Endurance RP
Endurance RP, through its wholly-owned subsidiary Plethora Solutions Limited, operates in the pharmaceutical industry, focusing on the development and commercialization of treatments for premature ejaculation. Its primary product, Senstend™, is a proprietary formulation of lidocaine and prilocaine, targeting a significant male population in China.
Technical Sentiment Signal: Buy
Current Market Cap: $13.52M
For detailed information about 0575 stock, go to TipRanks’ Stock Analysis page.